|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 104, 1340-1348, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
S Hasegawa, H Yokomise, T Hirai, T Fukuse, K Muro, Y Takahashi, K Inui, M Aoki, S Hitomi and H Wada
The immunosuppressive potency and the side effects of combination therapy
with FK 506 and cyclosporine A were studied in dogs that had undergone lung
transplantation. The animals were divided into four groups: group A (one
third optimal FK 506 dose: FK 506, 0.03 mg/kg intramuscularly) (n = 5),
group B (one third optimal cyclosporine dose: cyclosporine 6 mg/kg orally)
(n = 5), group C (one third FK 506 and one third cyclosporine optimal
doses): FK 506, 0.03 mg/kg intramuscularly plus cyclosporine 6 mg/kg
orally) (n = 5), and group D (half FK 506 plus half cyclosporine optimal
doses: FK 506, 0.05 mg/kg intramuscularly, plus cyclosporine, 10 mg/kg
orally) (n = 10). Assessments including chest x-ray film, fiberoptic
bronchoscopy, hematologic and biochemical tests, FK 506 and cyclosporine
blood trough level measurement, right pulmonary artery occlusion test, and
histopathologic observations were performed. In group A two of five dogs
survived 28 days and three died on postoperative days 7, 14, and 21. In
group B one dog survived 28 days and four died on postoperative days 9 (two
dogs), 14, and 21. Histologic examination showed severe rejection in both
group A and group B. In group C all five dogs survived 28 days but showed
mild rejection. In group D one dog died of intestinal bleeding on
postoperative day 7 and nine survived 28 days. No pathologic changes were
observed except in one case of mild rejection. The ventilation function of
the transplanted lung was poor in groups A, B, and C but good in group D.
No abnormal rise of FK 506 and cyclosporine trough levels was observed.
There were no significant side effects and abnormal hematologic and
biochemical data except in one dog in group D. We concluded (1) the
combination of FK 506, 0.03 mg/kg, and cyclosporine, 6 mg/kg, is much more
effective than either drug used singly, (2) the combination of FK 506, 0.05
mg/kg, and cyclosporine, 10 mg/kg, prevents rejection with tolerable side
effects, and (3) no worse side effects are caused by combination therapy
with FK 506 and cyclosporine than by either one used singly.
ARTICLES
Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation
Department of Thoracic Surgery, Kyoto University, Japan.
This article has been cited by other articles:
![]() |
T. Bando, S. Kosaka, C. Liu, T. Hirai, T. Hirata, H. Yokomise, K. Yagi, K. Inui, S. Hitomi, and H. Wada Effects of newly developed solutions containing trehalose on twenty-hour canine lung preservation J. Thorac. Cardiovasc. Surg., July 1, 1994; 108(1): 92 - 98. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |